Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: A multicenter randomized phase III study

Onkologie

Volumn 28, Issue 6-7, 2005, Pages 347-350

  Hartung, G ^a,l   Hofheinz, R D ^b   Dencausse, Y ^b   Sturm, J ^c   Kopp Schneider, A ^d   Dietrich, G ^e   Fackler Schwalbe, I ^f   Bornbusch, D ^g   Gonnermann, M ^h   Wojatschek, C ⁱ   Lindemann, W ^j   Eschenburg, H ^k   Jost, K ^a   Edler, L ^d   Hochhaus, A ^b   Queisser W ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Inst of Anat and Cell Biology III   (Germany)

^c MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e Krankenhaus Bietigheim Bissingen   (Germany)

^f Klinikum Passau   (Germany)

^g Chirurgische Klinik   (Germany)

^h EVANGELISCHES KRANKENHAUS   (Germany)

ⁱ Klinikum am Plattenwald   (Germany)

^j Medizinische Klinik   (Germany)

^k Arztpraxis   (Germany)

^l ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

more..

Author keywords

Adjuvant therapy; Colon cancer; Edrecolomab; Stage II

Indexed keywords

CELL SURFACE PROTEIN; EDRECOLOMAB;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT CODING; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 20444452496     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084595     Document Type: Article

References (17)

1. Chau I, Chan S, Cunningham D: Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives. Clin Colorectal Cancer 2003;3:19-33.
2. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, for the Multicenter International Study of Oxaliplatin/5- Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
3. Arnheim K: Oxaliplatin beim Kolorektalkarzinom: Von der Palliation zur Kuration. Onkologie 2004;27 (Suppl):2-11.
4. Wein A, Hahn EG, Merkel S, Hohenberger W: Adjuvant chemotherapy for stage II (Dukes' B) colon cancer: too early for routine use. Eur J Surg Oncol 2000;26:730-732.
5. Schwartzberg LS: Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol 2001; 40:17-24.
6. Riethmüller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Cohort. Lancet 1994; 343:1177-1183.
7. Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R: Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16: 1788-1794.
8. Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones D, Dethling J, Colman J, Coward L, MacGregor S: Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002;360:671-677.
9. Zelen M: A new design for randomized clinical trials. N Engl J Med 1979;300:1242-1245.
10. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
11. Franz A, Bewersdorf H, Hartung G, Dencausse Y, Queißer W: Exacerbation of Wegener's granulomatosis following single administration of monoclonal antibody 17-1A (Panorex) during adjuvant immunotherapy of colon cancer. Onkologie 2000; 23:472-474.
12. Sargent DJ, Wieand S, Benedetti J, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G, De Gramont A, Goldberg RM: Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. Proc Am Soc Clin Oncol 2004;20:3502 (abstract).
13. Colacchio TA, Niedzwiecki D, Compton C, Warren R, Benson A, Goldberg R, Kerr D, Fields A, Hollis D, Mayer R: Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). Proc Am Soc Clin Oncol 2004;20: 3522 (abstract).
14. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999;17:1356-1363.
15. Taal BG, Van Tinteren H, Zoetmulder FAN on behalf of the NACCP group: Adjuvant 5-FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001;85: 1437-1443.
16. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:1797-1806.
17. Zaniboni A, Labianca R: Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann Oncol 2004;15:1310-1318.